McGeorge will also serve as chair of the Magenta audit committee.
McGeorge is an operating partner at Havencrest Healthcare, a growth equity fund specializing in the healthcare industry; and a board member at Dioko Health Ventures, a healthcare venture fund.
She previously spent more than a decade as managing partner of the US and Global Healthcare practice at Grant Thornton, an independent audit, tax and advisory firm; and prior to that was a healthcare partner at audit and tax firms Deloitte, LLP and Arthur Andersen, LLP.
McGeorge is a member of the board of directors and the audit/finance and new technology committees of Be The Match, a non-profit organization dedicated to helping patients access life-saving stem cell transplants.
She also sits on the steering committee of the Carolinas and Tampa Bay chapters of 2020 Women on Boards, an organization focused on increasing diversity on public company boards.
McGeorge teaches a financial leadership course at the University of North Carolina, Chapel Hill, Gillings School of Public Health.
McGeorge earned a B.B.A. in accounting from the College of William and Mary, and an M.S. in Accounting from the University of Virginia.
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases.
Santhera Pharmaceuticals signs Gulf region distribution agreement with Uniphar
Novo Nordisk expands legal action over compounded 'semaglutide'
Neuraxpharm launches Neuraxpharm Australia
OncoZenge selects Meribel Pharma as CDMO for Phase 3 BupiZenge project
Fridays nominated for World Out of Home awards for weight loss campaign
Physiomics expands into biometrics with two contract wins and new division head
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
iOncologi acquires TargImmune Therapeutics
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'